TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
Feature|Articles|September 18, 2026
Understanding the Latest with MFN Pricing and What It Means to Pharma
Author(s)Alan Crowther
EVERSANA's Alan Crowther on why MFN's three programs, compounding interactions with IRA and 340B, and leverage gaps make it pharma's most consequential pricing challenge.
Advertisement
Advertisement
On August 31, the Trump Administration expanded its Most-Favored-Nation (MFN) drug pricing initiative by securing agreements with nine additional pharmaceutical companies. Pharmaceutical Executive connected with Alan Crowther, who leads EVERSANA’s global pricing and access business and the company’s leading pricing platform, Navlin, to discuss what the updates to MFN could mean to the industry.
Related to this article
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Fox Rothschild's Mark Wagner on why drug shortages are so hard to fix — from the definition gap to API dependency to three-year site approvals.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Advertisement
Advertisement